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Abstract 
Background: The new microcapillary and fluorescence‑based EC IVD‑qualified Muse™ Auto CD4/CD4% single‑
platform assay (EMD Millipore Corporation, Merck Life Sciences, KGaA, Darmstadt, Germany) for CD4 T cell numeration 
in absolute number and in percentage was evaluated using Central African patients’ samples compared against the 
reference EC IVD‑qualified BD FACSCount (Becton–Dickinson, USA) flow cytometer.
Methods: EDTA‑blood samples from 124 adults, 10 adolescents, 13 children and 3 infants were tested in parallel at 2 
reference laboratories in Bangui.
Results: The Muse™ technique was highly reproducible, with low intra‑ and inter‑run variabilities less than 15%. CD4 
T cell counts of Muse™ and BD FACSCount in absolute number and percentage were highly correlated (r2 = 0.99 and 
0.98, respectively). The mean absolute bias between Muse™ and BD FACSCount cells in absolute number and percent‑
age were −5.91 cells/µl (95% CI −20.90 to 9.08) with limits of agreement from −77.50 to 202.40 cells/µl, and +1.69 
%CD4 (95% CI ±1.29 to +2.09), respectively. The percentages of outliers outside the limits of agreement were nearly 
similar in absolute number (8%) and percentage (10%). CD4 T cell counting by Muse™ allowed identifying the major‑
ity of individuals with CD4 T cell <200, <350 or <750 cells/µl corresponding to the relevant thresholds of therapeutic 
care, with sensitivities of 95.5–100% and specificities of 83.9–100%.
Conclusions: The Muse™ Auto CD4/CD4% Assay analyzer is a reliable alternative flow cytometer for CD4 T lympho‑
cyte enumeration to be used in routine immunological monitoring according to World Health Organization recom‑
mendations in HIV‑infected adults as well as children living in resource‑constrained settings.
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Background
In 2013, the World Health Organization (WHO) pub-
lished the first consolidated guidelines on the use of 
antiretroviral treatment (ART) for HIV treatment and 
prevention across all age groups and populations [1]. The 
2013-revised WHO guidelines emphasized the need for 
laboratory monitoring, firstly based on immunological 
assessment of CD4 T lymphocytes numeration to start 
ART and monitor treated patients and secondly based 
on HIV-1 RNA load, in order to monitor treatment effi-
cacy, early therapeutic failure and therapeutic switch 
in patients on ART [2–5]. More recently, the ambitious 
UNAIDS Fast-Track targets for 2020, refers to achieving 
major reductions in HIV-related mortality and new HIV 
infections and the 90–90–90 targets, pushed countries 
to further accelerate their HIV responses in the coming 
years. A comprehensive revision of the WHO guidelines 
on the use of ART has been undertaken in 2015 and based 
on new scientific evidence and lessons from antiretroviral 
programs implementation [6] and recently consolidated 
in 2016 [7]. Basically, the key recommendation that was 
developed during the WHO revision process in 2015 and 
2016 is that ART should be initiated in everyone living 
with HIV at any CD4 T cell count [6, 7]. Indeed, earlier 
use of ART results in better clinical outcomes for people 
living with HIV compared with delayed treatment. The 
HIV-1 RNA load remains the principal biological marker 
to monitor ART efficacy and early therapeutic failure [6, 
7]. However, CD4 T cell counting remains currently an 
important biological marker for ART monitoring for at 
least 4 major reasons: (1) The marker is well known to 
physicians and largely implemented throughout Africa; 
(2) WHO thresholds for ART initiation as a priority 
remains based on CD4 T cell enumeration while ART is 
not universally available; (3) Immunological failure may 
be important to diagnose in order to confirm therapeutic 
failure by targeted HIV-1 viral load when HIV load is not 
universally implemented; and finally (4) CD4 T cell levels 
are important to determine the prophylaxis of opportun-
istic infections. Finally, CD4 T cell counting will remain 
an important biological marker for ART during the next 
few years.
A number of technologies are available for CD4 T cell 
enumeration, with considerable variation in cost, com-
plexity and operating requirements [8–10]. The tradi-
tional approach to measure absolute CD4 T lymphocyte 
counts is to use the total leukocyte count (or lymphocyte 
count) obtained from the hematology analyzer and then 
use the percentage of CD4 T lymphocytes from the flow 
cytometric analysis to calculate the absolute values—the 
so-called “dual platform” (DP) approach, which is how-
ever often associated with inter-laboratory variation as 
high as 40% [9, 10]. Thus, the need to derive accurate and 
precise absolute CD4 T lymphocyte counts has led to the 
development of instruments that can produce both per-
centage and absolute values, termed “single-platform” 
approach. Affordable CD4 T cell counting has gradually 
become possible by using simple, compact, robust and 
low-cost new generation cytometers operating as sin-
gle-platform volumetric instruments without the use of 
expensive microbeads [9, 11–20]. The recently developed 
Muse™ Auto CD4/CD4% system (EMD Millipore Cor-
poration, Merck Life Sciences, KGaA, Darmstadt, Ger-
many) consists of a compact, portable and easy-to-use 
cell analyzer, software and optimized reagents.
Finally, the aim of the present study was to evaluate 
the usefulness of the simplified Muse™ Auto CD4/CD4% 
system for CD4 T cell numeration in absolute count and 
in percentage, compared against reference flow cytom-
etry method. Because it is critical that country programs 
consider whether CD4 analyzers can give accurate and 
reproducible results, as well as being appropriate for the 
setting, we focused our field evaluation on bias and mis-
classification probabilities of different CD4 T cell thresh-
olds that are important for ART initiation as a priority 
according to WHO guidelines.
Methods
Clinical specimens and processing
In June 2016, tri-potassium ethylenediaminetetraacetic 
acid (K3-EDTA)-blood samples obtained by venipuncture 
in Vacutainer tubes (Becton–Dickinson, Franklin Lakes, 
NJ, USA) were received from HIV-1-infected patients fol-
lowed for routine biological monitoring. The monitoring 
was conducted at the Centre National de Référence des 
Infections Sexuellement Transmissibles et de la Thérapie 
Antirétrovirale («CNRISTTAR»), Bangui, Central Afri-
can Republic, which is a research laboratory devoted to 
HIV screening and monitoring, affiliated to University of 
Bangui. HIV-1-infected children attending the Complexe 
Pédiatrique of Bangui for their antiretroviral treatment 
follow up were also included. Two aliquots were kept at 
ambient temperature. No extra specimens were required. 
All blood samples were anonymous, unlinked to identi-
fiers and no mention of possible antiretroviral treatment 
could be made. Each aliquot was first subjected to CD4 
T cell count by Muse™ Auto CD4/CD4% system, within 
1 h, at the CNRISTTAR. The second aliquot was used in 
parallel, within 1 h, at the Laboratoire National de Biol-
ogie Clinique et de Santé Publique of Bangui, The HIV 
National Reference Laboratory, for measurement on BD 
FACSCount (Becton–Dickinson), a dedicated reference 
clinical instrument for CD4 T cell counting [9], chosen as 
flow cytometry reference analyzer.
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CD4 T cell measurements
CD4 T cell counting was performed in parallel on 2 dif-
ferent systems: (1) the BD FACSCount; and (2) the 
Muse™ Auto CD4/CD4% system. Both the BD FACS-
Count and the Muse™ Auto CD4/CD4% systems are 
based on the flow cytometry principle, using BD FACS-
Count and Muse™ softwares enable automated identi-
fication of the lymphocyte populations of interest, and 
calculation of the CD4 T cells in absolute counts and 
percentages.
The BD FACSCount consists of a single-platform 
benchtop, a modified flow cytometer, using a standard 
reagent kit [9]. The instrument is equipped with a green 
laser for excitation of 2 fluorescent parameters: phyco-
erythrin (PE) and tandem fluorochrome composed of 
PE and indodicarbocyanine (Cy™5) (PE-Cy™5). Recently, 
new reagents and software have been updated to allow 
the additional measurements of CD4% essential for mon-
itoring paediatric patients in addition to absolute CD4 T 
cell [21–23]. In this study, the new FACSCount CD4 rea-
gent kit was used, consisting of a single tube containing 
a mixture of 3 monoclonal antibodies, CD4/CD14/CD15 
(conjugated with PE/PE-Cy™5/PE-Cy™5, respectively), 
a nuclear DNA fluorescent dye and a known number of 
fluorescent microbeads. Monoclonal antibody to CD14 
recognizes a human monocyte/macrophage antigen, 
whereas monoclonal antibody to CD15 recognizes a 
human myelomonocytic antigen.
The Muse™ Auto CD4/CD4% system consists of a com-
pact, portable and easy-to-use cell analyzer, software 
and optimized reagents. The Muse™ analyser uses novel, 
miniaturized optics and microcapillary laser technology. 
In brief, a sample of fluorescent labeled cells is aspirated 
into a uniquely proportioned microcapillary flow cell. A 
green laser excites the cells and each cell emits a signal 
that is individually detected by photomultipliers and a 
photodiode. The Muse™ Auto CD4/CD4% kit is intended 
to be performed on a Muse™ Cell Analyzer with Muse™ 
Auto CD4% Software, which includes 3 modules: Muse™ 
Auto CD4/CD4%, System Check and Complete System 
Clean. The Muse™ Auto CD4/CD4% kit is intended to 
identify and quantify both absolute CD4 T cell counts 
and CD4% values in whole blood samples. The kit con-
sists of the Muse™ Auto CD4/CD4% antibody cocktail, a 
proprietary mixture of antihuman lymphocyte antibod-
ies and a monoclonal anti-human CD4 antibody. The kit 
also contains Muse™ 1× Lysing Solution to lyse erythro-
cytes. The anti-human lymphocyte antibodies detect all 
human lymphocytes. The CD4 antibody identifies human 
CD4-positive helper/inducer T cells (HLA Class II reac-
tive) and recognizes a 60-kDa surface antigen. Mono-
cytes also express CD4 but at lower density and have no 
co-expression of the other lymphocyte markers detected 
by reagents in this kit. The CD4% values are the absolute 
counts of the CD4 T helper cells expressed as a percent-
age of total lymphocytes in EDTA whole blood samples 
from adult and pediatric donors. All relevant data and 
results are immediately available.
To ensure quality control of the Muse™ Auto CD4/
CD4% system and the reference flow cytometric BD FAC-
SCount with regard to the performances of the analyzers, 
the same lots of reagents were used throughout the study. 
To assess the accuracy of the reference BD FACSCount 
system, internal quality control reagents consisting of 3 
known concentrations of fluorochrome-integrated beads 
[low (50  beads/µl), medium (250  beads/µl) and high 
(1000 beads/µl)] were analyzed prior to measuring each 
batch of stained whole blood samples. Systematic con-
tractual maintenance of the BD FASCCount analyzer 
was carried out each year by Becton–Dickinson, Douala, 
Cameroon. Finally, external quality control of the refer-
ence BD FACSCount platform at Laboratoire National 
de Biologie Clinique et de Santé Publique of Bangui was 
organized each year by the medical biology laboratory of 
hôpital Européen Georges Pompidou, Paris, France.
Assessment of the precision of CD4 T cell counting 
by Muse™ Auto CD4/CD4
The precisions of CD4 T cell counting on the Muse™ Auto 
CD4/CD4% system, including intra-assay (as an evalua-
tion of the repeatability) and inter-assay (as an evaluation 
of the reproducibility) variations, were assessed using 3 
different EDTA-blood samples stored at room tempera-
ture with CD4 T cell counts of clinical interest (<200; 
200–350;  >750  cells/µl). The intra-assay variation, which 
assesses the tube-to-tube variability, including errors 
due to operator, was determined by repeating the entire 
CD4 staining procedure 10 times on the 3 blood samples. 
Inter-assay variation (day-to-day) takes into account the 
variations of pipetting made by the technician (tube-to-
tube variability). This was assessed by repeating the entire 
procedure 10 times on 3 separate days, including pipet-
ting, sample preparation, staining and sample acquisition, 
in the 3 pools. Interperson variation (between different 
technicians) was not assessed. Precision was expressed 
as the coefficient of variance (CV) obtained by dividing 
the standard deviation (SD) of all measurements by their 
mean (CV% = SD × 100/mean) [24].
Statistical analyses
The following definitions for adults, adolescents, chil-
dren and infants were used according to the 2015-revised 
WHO recommendations [6]: an adult is a person older 
than 19 years, an adolescent is a person 10–19 years old 
inclusive, a child is a person younger than 10 years and an 
infant is a child younger than 1 year of age.
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The Method Validator software, version 1.1.9.0. 
(Philippe Marquis, France) and the SAS-PC software 
(version 8.2, SAS Institute, Cary, NC, USA) were used for 
statistical analyses. Firstly, correlations between the abso-
lute and percentage CD4 T cell counts obtained by the 
reference BD FACSCount system and the Muse™ Auto 
CD4/CD4% system were established by the unweighted 
linear regression as well as the Passing-Bablok nonpara-
metric method which is fairly less sensitive to outliers 
[25]. The level of significance for correlation tests was set 
at α < 0.05. Secondly, the agreement between BD FACS-
Count system and Muse™ Auto CD4/CD4% system was 
depicted by different plots as proposed by Bland and 
Altman [26, 27]. The Bland–Altman analysis examines, 
in a discriminative fashion, whether the methods agree 
sufficiently well to be used interchangeably. The aver-
age of values obtained by the 2 methods is displayed on 
the x axis and plotted against the difference between 
the 2 methods shown on the y axis. The average differ-
ence between the 2 methods, referred to as bias, was 
marked on the graph by a horizontal line and the limits of 
agreement with a 95% confidence interval (CI) were also 
depicted.
The sensitivities and specificities of the Muse™ Auto 
CD4/CD4% system to diagnose patients according to dif-
ferent relevant WHO thresholds of therapeutic care were 
evaluated in the field. Thus, the threshold of 200  cells/
µl corresponds to the threshold of immune-restauration 
under ART and the threshold for therapeutic initiation 
according to the 2006-revised WHO recommendations 
[28]. The threshold of 350  cells/µl corresponds to the 
WHO threshold for antiretroviral treatment initiation in 
adults and children aged more than 5 years according to 
the 2010-revised WHO guidelines [29] and the thresh-
old for antiretroviral treatment initiation as a priority for 
adults, adolescents (10–19  years old) and children aged 
more than 5  years according to the 2015-revised WHO 
guidelines [6] and to the 2016-consolidated WHO guide-
lines [7]. Finally, the threshold of 750 CD4 T cells/µl and 
25 %CD4+ correspond to the absolute and percent CD4 
T cell count 2010-revised WHO thresholds for antiret-
roviral treatment initiation in children aged between 24 
and 59 months [29] and the thresholds for antiretroviral 
treatment initiation as a priority for children aged more 
than 2 years and less than 5 years [6, 7].
For clinical significance of the measurement differences 
on treatment decision, the Cohen’s κ coefficient was cal-
culated on study population (http://faculty.vassar.edu/
lowry/kappa.html) [30].
Ethics statement
We used the excess of routine blood samples from HIV-
infected patients attending the CNRISTTAR or the 
Complexe Pédiatrique for routine CD4 T cell enumera-
tion. Blood sample records were made anonymous and 
identified by giving them a consecutive study code prior 
to analysis. The study was formally approved by the Sci-
entific Committee of Faculté des Sciences de la Santé 
(“FACSS”) of Bangui, (so-called “Comité Scientifique de 
la Validation des Protocoles et des Résultats de Recherche 
en Santé”/“CSVPR”) constituting the National Ethical 
Committee (agreement #2UB/FACSS/CSVPR). Finally, 
the return of laboratory results to clinicians was con-
ducted to achieve a better management of the treated 
patient. Feedback was given to the children’s parents 
and their pediatricians on all tested parameters car-
ried out during the study period, allowing changes of 
antiretroviral treatment and improvement of medical 
care. All participants, including children’s guardians or 
parents, signed an informed consent. For the purpose 
of this independent study, the Muse™ Auto CD4/CD4% 
and FACSCount CD4 reagents were purchased. Further-
more, EMD Millipore Corporation was never involved in 
running and/or analyzing the samples and/or writing the 
present paper.
Results
Precision of CD4 T cell measurements by Muse™ Auto CD4/
CD4% system
The intra-assay and inter-assay CVs were tested using 
3 blood samples in total, one for each range of low 
(<200  cells/µl), middle (between 200 and 350  cells/µl) 
and high (>750  cells/µl) CD4 T cell counts (e.g. within 
the ranges of values of medical interests). The results are 
shown in Table 1.
For CD4 T cell expressed in absolute number, the mean 
intra-assay CVs of Muse™ Auto CD4/CD4% system 
was 8.5%; the inter-assay CVs of the analyzer appeared 
slightly higher than intrarun CVs for CD4 T cell counts 
below 350  cells/µl, with a mean interrun variability of 
10.4%.
For CD4 T cell expressed in percentage, the mean 
intra-assay CVs of Muse™ Auto CD4/CD4% system was 
4.4%; the inter-assay CVs of the analyzer appeared higher 
than intra-assay CVs for all CD4 T cell counts, with a 
mean interrun variability of 11.2%.
Thus, the repeatability appeared generally higher 
than the reproducibility for CD4 T cell measurements 
expressed in absolute number or in percentage. Further-
more, the reproducibility of CD4 T cell measurement in 
percentage was slightly higher than the reproducibility 
of CD4 T cell measurement in absolute number, at each 
level of CD4 T cell. Nevertheless, the repeatabilities and 
reproducibilities were always below 15% whatever the 
CD4 T cell levels and the CD4 T cell expression (absolute 
number or percentage).
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Accuracy of CD4 T cell measurements by Muse™ Auto CD4/
CD4% system
Parallel CD4 T cell measurements on both instruments, 
the Muse™ Auto CD4/CD4% system and BD FACSCount 
system, were done for a total of 150 tested blood samples, 
obtained from study patients (median age of 36  years; 
range 0.7–66  years; 106 females), including 124 adults 
(over 19 years), 10 adolescents (10–19 years old), 13 chil-
dren (from 1 to 9 years) and 3 infants (under 1 year).
The accuracy of CD4 T cell measurements by the 
Muse™ Auto CD4/CD4% system was carried out against 
the results obtained by the BD FACSCount system cho-
sen as reference for CD4 T cell counting. The absolute 
bias (and the limits of agreement) for CD4 T cell counting 
in absolute count and percentage are shown in Tables 2 
and 3 for the study in adults and children, by the Muse™ 
Auto CD4/CD4% system and the BD FACSCount sys-
tem. In addition, the Fig. 1 depicts the unweighted linear 
and the Passing-Bablok regressions; the Fig. 2 shows the 
Bland–Altman analyses between the CD4 T cell count 
results obtained by Muse™ Auto CD4/CD4% system and 
BD FACSCount flow cytometer, in absolute number, in 
the 140 study HIV-1-infected adults, adolescents and 
children more than 5  years and 10 HIV-1-infected chil-
dren and infants less than 5 years; and the Fig. 3 depicts 
the Passing-Bablok regression and the Bland–Altman 
agreement when the CD4 T cell count obtained from the 
same population are expressed in percentage.
Mean  ±  SD of CD4 T cell/µl expressed in absolute 
number was 1003  ±  1397 cells/µl (range 15–2113) by 
Muse™ Auto CD4/CD4% system and 940 ±  1325 cells/
µl (range 16–2203) by BD FACSCount flow cytom-
eter (P > 0.5). The unweighted linear regression analysis 
on all 150 available T cell results expressed in absolute 
count revealed a high correlation between CD4 T cell 
counts obtained by Muse™ Auto CD4/CD4% system 
and BD FACSCount flow cytometer (Fig.  1a). Simi-
larly, the non-parametric Passing-Bablok regression 
analysis showed high correlation between Muse™ Auto 
CD4/CD4% system and BD FACSCount flow cytomete 
(r2 =  0.99) with a slope of 0.98 (95% IC 0.96–1.00) and 
an intercept of +8.1 (95% CI −1.8 to 16.2) [<200 cells/ml: 
r2 = 0.87, slope = 0.86, intercept = +33.1; 200–350 cells/
ml: r2 = 0.97, slope = 0.95, intercept = +3.1; >350 cells/
ml: r2 =  0.98, slope =  0.98, intercept = −7.7] (Fig. 1b). 
The relation between Muse™ Auto CD4/CD4% system 
and BD FACSCount flow cytometer did not differ from 
linearity (P > 0.4). The mean absolute bias measured by 
Bland–Altman analysis between CD4 T cell/µl obtained 
by Muse™ Auto CD4/CD4% system and BD FACS-
Count flow cytometer over the entire range of CD4 T 
cell results, were −5.91 cells/µl (95% CI −20.90 to 9.08) 
with limits of agreement from −77.50 to 202.40 cells/µl 
(Fig. 2).
Analysis of CD4 T cell count measurement expressed 
in percentage showed a high correlation and a close 
Table 1 Intra-assay (as an estimation of the repeatability) and inter-assay (as an estimation of the reproducibility) pre-
cisions of  single-platform Muse™ Auto CD4/CD4% system for  CD4 T cells measurement, expressed in  absolute number 
and in percentage
* Mean ± standard deviation of results obtained by tenfold repeating the same day acquisition on Muse™ Auto CD4/CD4% system of the blood sample of each range 
of CD4 T cells
** Mean ± standard deviation of results obtained by tenfold repeating on 3 separate days acquisition on Muse™ Auto CD4/CD4% system of the blood sample of each 
range of CD4 T cells
*** Precision is the coefficient of variance (CV) obtained by dividing the standard deviation (SD) of all the intrarun or interrun measurements by their mean 
(CV% = SD × 100/mean); the mean CV is the mean of the 3 CVs calculated at 3 different counts of blood CD4 T cells
**** Intrarun CVs obtained with BD FACSCount (Becton–Dickinson, Franklin Lakes, NJ, USA) previously estimated in Dar es Salam (Tanzania) was 6.8% for CD4 T cell 
counts expressed in absolute number and 5.0% for CD4 T cell counts in percentage [41]
***** Interrun CVs obtained with BD FACSCount (Becton–Dickinson, Franklin Lakes, NJ, USA) estimated in Dar es Salam (Tanzania) were 8.0% for low CD4 T cell counts 
expressed in absolute number and 7.9% for low CD4 T cell counts in percentage; and 7.0% for high CD4 T cell counts expressed in absolute number and 5.6% for high 
CD4 T cell counts in percentage [41]





















<200 cells/µl 161.5 ± 14.9 9.2 199.7 ± 20.8 10.4 19.0 ± 0.8 4.3 16.0 ± 1.8 11.0
200–350  
cells/µl
266.1 ± 15.1 5.7 252.8 ± 33.5 13.2 16.6 ± 0.8 5.1 13.7 ± 1.8 13.7
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agreement between both CD4 T cell counting meth-
ods, similarly to CD4 T cell count expressed in absolute 
numbers. Mean ± SD CD4 T cell count in percentage 
was 15.5 ± 20.5 %CD4+  (range 1–59) by Muse™ Auto 
CD4/CD4% system and 13.0  ±  18.4 %CD4+ (range 
0–50) by BD FACSCount flow cytometer (P  >  0.5). 
Results of CD4 T cell count in percentage by Muse™ 
Auto CD4/CD4% system and BD FACSCount flow 
cytometer were highly correlated by non-parametric 
Passing-Bablok regression analysis (r2  =  0.98) with a 
slope of 1.00 (95% IC 0.97–1.05) and an intercept of 
+1.4 (95% CI +0.4 to +2.3) [<200 cells/ml: r2 =  0.99, 
slope  =  1.02, intercept  =  +1.4; 200–350  cells/ml: 
r2  =  0.96, slope =  0.91, intercept =  +2.7;  >350 cells/
ml: r2 = 0.97, slope = 1.03, intercept = +0.9] (Fig. 3a), 
as well as unweighted linear regression analysis (not 
shown). The relation between Muse™ Auto CD4/
CD4% and BD FACSCount did not differ from linearity 
(P > 0.5). The mean of absolute bias between percent-
age of CD4 T cell obtained by Muse™ Auto CD4/CD4% 
system and BD FACSCount flow cytometer was +1.69 
%CD4 (95% CI ±1.29 to +2.09) with limits of agree-
ment from −1.65 to +6.67 %CD4.
The numbers of outliers outside the limits of agreement 
were similar when the CD4 T cell count was expressed 
in absolute count (12/150  =  8%) as when it was given 
Table 2 CD4 T cell counting in  absolute count and  percentage in  150 HIV-1-infected patients living in  Central African 
Republic, including 124 adults, 10 adolescents, 13 children and 3 infants, by the single-platform Muse™ Auto CD4/CD4% 
system and by the BD FACSCount system
SD standard deviation
a The Bland–Altman analysis was carried out to calculate the absolute bias and limits of agreement which are the 95% confidence intervals (±1.96 × SD) of the mean 
bias of all paired measurements in a given category (27)
Categories Adults, adolescents and children ≥ 5 years Children < 5 years and infants
Number 140 10
Absolute CD4 T cells (cells/µl)
 Muse™ Auto CD4/CD4% system
  Mean ± SD 1003 ± 1397 1263 ± 1081
 BD FACSCount system
  Mean ± SD 940 ± 1325 1203 ± 1056
 Absolute bias (limits of agreement)a
  Mean (±1.96 SD) +62.5 (−77.4; +202.4) +60.0 (10.1; +109.8)
Percent CD4 T cells (%CD4)
 Muse™ Auto CD4/CD4% system
  Mean ± SD 15.5 ± 20.5 17.5 ± 14.8
 BD FACSCount system
  Mean ± SD 13.0 ± 18.4 18.0 ± 16.9
 Absolute bias (limits of agreement)a
  Mean (±1.96 SD) +2.5 (−1.6; +6.7) −0.5 (−4.6; +3.6)
Table 3 CD4 T cell counting in absolute count and percent-
age in 150 HIV-1-infected patients living in Central African 
Republic, by  the single-platform Muse™ Auto CD4/CD4% 
system and  by the BD FACSCount system, at  various CD4 
T cell count ranges according to the BD FACSCount system 
results
SD standard deviation
a The Bland–Altman analysis was carried out to calculate the absolute bias and 
limits of agreement which are the 95% confidence intervals (±1.96 × SD) of the 
mean bias of all paired measurements in a given category [27]
Categories <200 cells/µl 200–350 cells/µl >350 cells/µl
Number 30 35 85
Absolute CD4 T cells (cells/µl)
 Muse™ Auto CD4/CD4% system
  Mean ± SD 90 ± 106 276 ± 13 1225 ± 1082
 BD FACSCount system
  Mean ± SD 79 ± 107 273 ± 4 1281 ± 844
 Absolute bias (limits of agreement)a
  Mean  
(±1.96 SD)
+9.5 (+2.6; +16.4) +11.5 (+4.6; +18.4) −73.0 (−491.5; +345.1)
Percent CD4 T cells (%CD4)
 Muse™ Auto CD4/CD4% system
  Mean ± SD 10.0 ± 12.7 20.0 ± 5.7 32.0 ± 2.8
 BD FACSCount system
  Mean ± SD 8.5 ± 12.0 16.0 ± 2.8 28.0 ± 2.9
 Absolute bias (limits of agreement)a
  Mean  
(±1.96 SD)
+0.5 (−0.8; +1.9) +3.0 (−5.3; +11.2) +1.0 (−7.3; +9.3)
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in percentage (15/150 = 10%) (P > 0.5 by Student t test) 
(Figs. 2, 3).
Finally, the Bland–Altman analysis on the relative dif-
ferences between the absolute and percent CD4 T cell 
counts obtained with Muse™ Auto CD4/CD4% system 
and BD FACSCount system with the average absolute 
CD4 T cell counts results showed a close agreement 
between both methods.
Identification of clinically-relevant thresholds by Muse™ 
Auto CD4/CD4% system
The sensitivity and specificity of CD4 T cell counting in 
absolute number on the Muse™ Auto CD4/CD4% system 
to identify relevant thresholds of CD4 T cell count accord-
ing to the WHO recommendations are depicted in Table 4.
The capability of the Muse™ Auto CD4/CD4% sys-
tem to identify patients having less than (or more than) 
200 CD4 T cell/µl was evaluated on the 150 available 
CD4 T cell count measurements. Taking into account 
a 10% bilateral range (i.e., counts between 190 and 210 
CD4 T cell/µl were considered similar), the concord-
ance between the Muse™ Auto CD4/CD4% system and 
BD FACSCount system was high (κ  =  0.98; P  <  0.01). 
The decision differed for only 1 study’s blood samples. 
Accordingly, the Muse™ Auto CD4/CD4% showed a sen-
sitivity of 96.7% and a specificity of 100% to identify indi-
viduals with CD4 T cell counts below 200 cells/µl when 
compared with the results obtained by the BD FACS-
Count system.
The sensitivity and specificity of CD4 T cell counting 
in absolute number on the Muse™ Auto CD4/CD4% sys-
tem to identify patients having less than (or more than) 
350 CD4 T cell/µl was also evaluated on the 150 avail-
able CD4 T cell count measurements. Considering a 10% 
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Fig. 1 Unweighted linear regression (a) and Passing‑Bablok regression (b) tests between CD4 T cell count measurements in 150 HIV‑1‑infected 
patients [including 124 adults (>19 years), 10 adolescents (10–19 years old), 13 children (>1 to 9 years) and 3 infants (<1 year)], expressed in absolute 
number (cells/µl) obtained in parallel by the Muse™ Auto CD4/CD4% system and by the reference BD FACSCount system. By unweighted linear 
regression, slope and Y‑intercept values for the resultant trend line were 0.973 (95% CI, [+0.941 to +1.005]) and 9.0 (95% CI, [−14.0 to +31.9]), 
respectively. By Passing‑Bablok regression, slope and Y‑intercept values for the resultant trend line were 0.988 (95% CI, [+0.962 to +1.014]) and 8.1 
(95% CI, [−1.8 to +16.2]), respectively. The diagonal dotted lines represent the ideal lines (no bias). The full lines represent the regression lines of the 
distribution
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bilateral range (i.e., counts between 332 and 367 CD4 T 
cell/µl), the concordance between the Muse™ Auto CD4/
CD4% system and BD FACSCount system was very high 
(κ = 1.0; P < 0.01). Accordingly, the Muse™ Auto CD4/
CD4% system had a sensitivity of 100% and a specificity 
of 100% to identify individuals with CD4 T cell counts 
below 350 cells/µl when compared with the results 
obtained by the BD FACSCount system.
Considering the thresholds relevant in children, the 
Muse™ Auto CD4/CD4% system correctly identified 
all children having less than 750 CD4 T cell/µl, consid-
ering a 10% bilateral range (i.e., counts between 675 
and 825 CD4 T cell/µl), but 5 children with less than 
750 CD4 T cell/µl were misclassified, providing a low 
specificity of 83.9%; the Muse™ Auto CD4/CD4% sys-
tem identified nearly all children correctly having less 
than   %CD4+  ≤25%, considering a 10% bilateral range 
(i.e., counts between 22.5 and 27.0 %CD4+), providing 
a sensitivity of 95.5%, without misdiagnosing (specific-
ity of 100%). Finally, the concordance between Muse™ 
Auto CD4/CD4% and BD FACSCount systems to accu-
rately classify patients according to the relevant pediatric 
thresholds was excellent in absolute counts as well as in 
percentages.
Discussion
In the present study, we demonstrated that the Muse™ 
Auto CD4/CD4% system, when operated by a labora-
tory technician, performs acceptably compared to the 
BD FACSCount system when used as the reference 
method for CD4 T cell measurement expressed in abso-
lute number as well as in percentage. The Muse™ Auto 
CD4/CD4% system flow cytometer results in absolute 
number and percentage gave perfect correlations with 
those obtained by the reference flow cytometer method. 
Through the Passing-Bablok regression analysis, the 
correlation was maintained over all the dynamic range 
of values in absolute number (until 2113 CD4 T cells/µl) 
as well as in percentage (until 59 %CD4+). CD4 T cell 
counting by Muse™ Auto CD4/CD4% system allowed to 
accurately identify the majority of individuals with CD4 
T cell below 200 cells/µl and all individuals with CD4 T 
cell below 350, 750 cells/µl and 25 %CD4+ demonstrat-
ing the capacity of the Muse™ Auto CD4/CD4% system 
to accurately assess the major thresholds in absolute 
number (200, 350 and 750 cells/µl) or in percentage (25 
%CD4+), used in clinical practice to initiate or follow 
ART in adults as children. The procedure was fast and 
needed only 30 min to be completed. The technique was 
found to be very easy to carry out and highly precise in 
terms of repeatability and reproducibility, with intra- 
and inter- run variabilities less than 15%, considered 
as acceptable for clinical use [10, 18]. The interperson 
variation, which could introduce further assay variation, 
was however not assessed in the present study. Further-
more, the number of included young children was low in 
our study, thus warranting further studies to fully con-
firm the interest of the system for CD4 T cell counting 
in children and infants. Taken together, these findings 
demonstrate that the Muse™ Auto CD4/CD4% system 
is a reliable, robust and cost-effective alternative flow 
cytometer for CD4 T lymphocyte enumeration to be 
used routinely for immunological monitoring accord-
ing to the WHO recommendations in HIV-infected 
adults as well as children living in resource-constrained 
settings.
The WHO strongly recommends scientific reports of 
effective validation of newly introduced, affordable CD4 
T cell measurement technologies, carried out in the field 
by several laboratories of different resource-poor coun-
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Fig. 2 Bland–Altman analyses on the relative differences between 
the CD4 T cell counts in 150 HIV‑1‑infected patients obtained by 
Muse™ Auto CD4/CD4% system and BD FACSCount system com‑
pared with the average CD4 T cell count in absolute number (cells/
µl). The full line represents the mean relative difference and the dotted 
lines represent the superior and inferior limits of agreement. The 
arrow corresponds to the x abscise axis
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the present independent validation of the Muse™ Auto 
CD4/CD4% system by two reference laboratories of Ban-
gui well fulfilled the WHO recommendations for valida-
tion of CD4 T cell assays in resource-poor settings. The 
BD FACSCount system was used as reference system for 
CD4 T cell counting in the present evaluation. Indeed, 
the BD FACSCount is the oldest dedicated flow cytom-
eter that has been extensively used since 1996 [32] and 
fully validated against reference flow cytometers in 
resource-limited settings [32–35].
The unique, patented micro-capillary flow cell tech-
nology used in the Muse™ Auto CD4/CD4% system 
eliminates the requirement for complicated sheath flow 
fluidics and enables absolute cell counts without the 
need for reference beads, making the system extremely 
compact, easy to maintain and simple to use. The scal-
ing up of public ART programs globally has led to an 
increased demand for CD4 T cell count tests [36], 
especially to assess treatment eligibility. Furthermore, 
because ART may not be universally provided, the WHO 
defined priorities for ART initiation, all adults and ado-
lescents with severe or advanced HIV clinical disease 
(WHO clinical stage 3 or 4) and individuals with CD4 
count ≤350 cells/mm3, as well as all children from aged 
3 to maximum 10  years old with severe or advanced 
HIV clinical disease (WHO clinical stage 3 or 4) and 
individuals with CD4%  <  25% (if under 5  years old) or 
CD4 count ≤350  cells/mm3 (if under and up to 5  years 
old) [6, 7]. Finally, CD4 T counting remains currently an 
important biological marker for antiretroviral treatment 
initiation and monitoring, while HIV-1 RNA load is not 
sufficiently available in the field. The speed of implemen-
tation of CD4 T lymphocyte count facilities has been 
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Reference BD FACSCount system (cells/µl) 
a b
Fig. 3 a Passing‑Bablok regression between CD4 T cell count measurements in 150 HIV‑1‑infected patients expressed in percentage obtained in 
parallel by the Muse™ Auto CD4/CD4% system and by the reference BD FACSCount system. Slope and Y‑intercept values for the resultant trend line 
were 1.00 (95% CI [0.999–1.009]) and +1.0 (95% CI [+0.2 to +1.0]), respectively. The diagonal dotted lines represent the ideal lines (no bias). The full 
lines represent the regression lines of the distribution. b Bland‑Altman analyses on the relative differences between the CD4 T cell counts obtained 
by Muse™ Auto CD4/CD4% system and BD FACSCount system compared with the average CD4 T cell count in percentage. The full line represents 
the mean relative difference and the dotted lines represent the superior and inferior limits of agreement. The arrow corresponds to the x abscise axis
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and has met challenges with technology selection, labo-
ratory infrastructure development, human resource 
training, cost-effectiveness, instrument maintenance and 
ensuring testing access and quality [14, 31, 37]. However, 
most conventional benchtop flow cytometer systems 
used for enumeration of CD4 T lymphocyte counts are 
relatively complex, costly, technically demanding and the 
instruments used, need constant maintenance. Costly 
maintenance, the need for well-trained laboratory staff 
and a cold chain to ship and store reagents, can limit the 
use of sophisticated analyzers. These systems are difficult 
to apply for routine use in most laboratories operating 
with poor facilities and in resource-limited settings. The 
Muse™ Auto CD4/CD4% system for CD4 T cell count-
ing allows minimizing the sources of variations, is less 
expensive, is small, is simple to use and yet reproducible. 
Similarly, previous studies have yet reported that point-
of-care non-flow cytometry-based CD4 T cell counting 
device, such as the PIMA™ CD4 from Alere (Alere, Jena, 
Germany) [38] or Partec CyFlow miniPOC from Partec 
(Partec GmbH, Munster, Germany) [39] may be inter-
changeable with the existing conventional CD4 T cell 
enumeration platforms [10]. All these more affordable 
CD4 dedicated flow cytometers introduced into the mar-
ket are thought to ensure decentralization of the HIV-
monitoring services [9, 10]. Indeed, point-of-care CD4 T 
cell counting technologies reduce the time and increase 
patient retention along the testing and treatment cascade 
compared to conventional laboratory-based testing [40], 
which are therefore considered to be useful tools to per-
form CD4 T cell counting for expedite result delivery.
Conclusion
In resources-limited settings, CD4 T cell count remains 
an essential biological monitoring marker to diagnose 
and monitor antiretroviral treatment failure, because of 
frequent lack of HIV viral load availability. The Muse™ 
Auto CD4/CD4% system constitutes a promising system 
for performing single-platform, absolute and percent 
CD4 T lymphocyte counts with excellent reproducibility 
and should facilitate wider access to CD4 T cell enumera-
tion for adults and children with HIV infection living in 
resource-constrained countries.
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Table 4 Sensitivity and  specificity of  CD4 T cell counting 
by the Muse™ Auto CD4/CD4% system to identify patients 
having less than (or more than) 200, 350, 750 CD4 T cells/
µl and  25 %CD4+, calculated on  the 150 available CD4 T 
cell count measurements, including  the reference results 
obtained by BD FACSCount
* 200 CD4 T cells/µl: threshold of immune‑restauration under antiretroviral 
treatment and the threshold for therapeutic initiation according to the 
2006‑revised WHO recommendations [28]
** 350 CD4 T cells/µl: WHO threshold for antiretroviral treatment initiation in 
adults and children aged more than 5 years according to the 2010‑revised WHO 
guidelines [29] and threshold for antiretroviral treatment initiation as a priority 
for adults, adolescents (10–19 years old) and children aged more than 5 years 
according to the 2015‑revised WHO guidelines [6] and to the 2016‑consolidated 
WHO guidelines [7]
*** 750 CD4 T cells/µl and 25 %CD4+: absolute and percent CD4 T cell count 
2010‑revised WHO thresholds for antiretroviral treatment initiation in children 
aged between 24 and 59 months [29] and thresholds for antiretroviral treatment 
initiation as a priority for children aged more than 2 years and less than 5 years 
according to the 2015‑revised WHO guidelines [6] and to the 2016‑consolidated 
WHO guidelines [7]
$ A 10% bilateral range (i.e., counts between 190 and 210 CD4 T cells/μl for the 
threshold at 200 CD4 T cells/μl; counts between 332 and 367 CD4 T cells/μl for 
the threshold at 350 CD4 T cells/μl; counts between 712 and 787 CD4 T cells/μl 
for the threshold at 750 CD4 T cells/μl; and counts 23.7 and 26.2 %CD4+ for the 
threshold at 25 %CD4+) was considered similar
a The sensitivity and specificity of CD4 T cell counting by the Muse™ Auto CD4/
CD4% system to identify patients having less than (or more than) 200 CD4 T 
cells/µl and 350 CD4 T cells/µl, were calculated on the 150 available CD4 T cell 








200 CD4 T cells/μl* 96.7 100 0.98
350 CD4 T cells/μl** 100 100 1.00
750 CD4 T cells/μl*** 100 83.9 0.89
25 %CD4+*** 95.5 100 0.95
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